Maze Therapeutics, Inc.
Maze Therapeutics, Inc.（MAZE）股东结构
基于 13F 申报与流通股数据，展示机构、内部人与公众持股结构；下方为前十大机构、机构动向与内部人交易。
SEC 13F · FMP · MAZE · 截至 2025年9月30日
股东结构概览
95
机构持有人数
▲ 20 vs Q2
$1.11B
机构持仓总市值
▲ $637.50M vs Q2
55.35M
总流通股
freeFloat 28.87%
42.97M
13F 申报持股数
▲ 4.13M vs Q2
机构持仓% = 13F 持股数 ÷ 总流通股。内部人% = 100 − 自由流通率。散户% = 自由流通率 − 机构%。数据来源：FMP /symbol-positions-summary + /shares-float + SEC EDGAR。
前10大机构持仓
MAZE 最大股东 · 机构持仓
Q3 2025 · SEC 13F
显示前 10 家
| 机构 | 持股数 | 占比 | 权重 | 市值 | 申报日 | 变动 |
|---|---|---|---|---|---|---|
TRV GP IV, LLC biological products, (no diagnostic substances) | 6.07M | 13.85% | 13.85% | $157.50B | Nov 13, 2025 | — held |
FRAZIER LIFE SCIENCES MANAGEMENT, L.P. biological products, (no diagnostic substances) | 4.57M | 10.42% | 10.42% | $118.43B | Nov 14, 2025 | ▼ 1 |
ARCH VENTURE MANAGEMENT, LLC biological products, (no diagnostic substances) | 4.12M | 9.40% | 9.40% | $106.83B | Nov 14, 2025 | — held |
DEEP TRACK CAPITAL, LP biological products, (no diagnostic substances) | 3.95M | 9.01% | 9.01% | $102.40B | Nov 14, 2025 | — held |
ALPHABET INC. biological products, (no diagnostic substances) | 2.41M | 5.50% | 5.50% | $62.56B | Nov 7, 2025 | — held |
AH CAPITAL MANAGEMENT, L.L.C. biological products, (no diagnostic substances) | 1.70M | 3.88% | 3.88% | $44.14B | Nov 14, 2025 | — held |
MATRIX CAPITAL MANAGEMENT COMPANY, LP biological products, (no diagnostic substances) | 1.65M | 3.77% | 3.77% | $42.88B | Nov 13, 2025 | ▼ 832.5K |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 1.33M | 3.04% | 3.04% | $34.62B | Nov 7, 2025 | ▲ 915.3K |
BLACKROCK, INC. biological products, (no diagnostic substances) | 1.32M | 3.00% | 3.00% | $34.12B | Nov 12, 2025 | ▲ 701.3K |
VR ADVISER, LLC biological products, (no diagnostic substances) | 1.23M | 2.81% | 2.81% | $31.91B | Nov 14, 2025 | NEW |
数据来源：SEC 13F 申报文件。变动标识：isNew / isSoldOut / changeInSharesNumber。
机构仓位变动
Q3 2025 对比上季度
Q3 2025
21
增持
+5.24M 股9
新建仓
首次建仓8
减持
−4.10M 股0
清仓
完全退出净股数变化（前50家）
+1.14M
+5.24M / −4.10M
净新增持仓人
+22
新建 9 个 / 退出 0 个
基于前50家最大机构持仓统计，全市场实际数量可能不同。
内幕交易买卖情绪
MAZE 内幕交易记录
数据来源：SEC Form 4
近期内部人员以卖出为主。 卖出可能源于预定的 10b5-1 计划，不代表负面展望。
6
买入笔数
19
卖出笔数
0.32
买卖比
$0M
卖出总金额
最近内幕交易记录
最近10条 · 仅普通股
| 姓名 · 职位 | 日期 | 类型 | 股数 | 价格 | 金额 | 交易后持股 | 申报 |
|---|---|---|---|---|---|---|---|
Coloma Jason V Chief Executive Officer | Jun 1, 2026 | Sale | 6,090 | $26.20 | $159.5K | 344.9K | Form 4 ↗ |
Coloma Jason V Chief Executive Officer | Jun 1, 2026 | Sale | 553 | $26.24 | $14.5K | 28.0K | Form 4 ↗ |
Bernstein Harold President, R&D & CMO | Jun 1, 2026 | Sale | 13,253 | $25.57 | $338.9K | 1.6K | Form 4 ↗ |
Bernstein Harold President, R&D & CMO | Jun 1, 2026 | Sale | 1,600 | $26.36 | $42.2K | 0 | Form 4 ↗ |
Dandekar Atul CSBO | May 29, 2026 | Sale | 7,500 | $26.34 | $197.6K | 24.8K | Form 4 ↗ |
Coloma Jason V Chief Executive Officer | May 22, 2026 | Sale | 4,504 | $26.00 | $117.1K | 376.6K | Form 4 ↗ |
Coloma Jason V Chief Executive Officer | May 26, 2026 | Sale | 25,582 | $26.02 | $665.5K | 351.0K | Form 4 ↗ |
Coloma Jason V Chief Executive Officer | May 22, 2026 | Sale | 2,478 | $26.00 | $64.4K | 28.5K | Form 4 ↗ |
Coloma Jason V Chief Executive Officer | May 15, 2026 | Sale | 1,822 | $26.00 | $47.4K | 381.1K | Form 4 ↗ |
Coloma Jason V Chief Executive Officer | May 15, 2026 | Sale | 116 | $26.00 | $3.0K | 31.0K | Form 4 ↗ |
数据来源：SEC Form 4。买卖方向：acquisitionOrDisposition A=买入，D=卖出。已排除 RSU 归属（M-Exempt）。
关于机构与内部人持股结构
Maze Therapeutics, Inc.（MAZE）主要由机构投资者持有，机构持股比例约为 77.6%。公司内部人员持股约 71.13%，散户及公众持股约占剩余的 0.00%。
Maze Therapeutics, Inc. 最大机构股东为 TRV GP IV, LLC，截至 September 30, 2025 持有约 6.07 million 股，占总流通股的 13.85%。
目前共有 95 家机构持有 MAZE 股票，合计持仓市值约 $1.11 billion，数据来源为最新 SEC 13F 申报。
常见问题
MAZE ownershipMaze Therapeutics, Inc.（MAZE）主要由机构投资者持有，机构持股约 77.6%。最大股东为 TRV GP IV, LLC，持股比例 13.85%。内部人员持股约 71.13%。数据来源 SEC Form 13F，截至 September 30, 2025。